
    
      This is a multicenter, randomized, open-label, active-controlled, parallel, phase III study
      which aims to assess the efficacy and safety of ferric citrate capsules for the treatment of
      hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis. This study
      is consisting of a Screening/Washout period (14 days) and a Treatment/Observation period (12
      weeks). During the Treatment period, the subjects will be randomly assigned to the ferric
      citrate capsule group (study group) or sevelamer carbonate tablet group (control group) in
      the ratio of 1:1.
    
  